Sugi Predict

Sugi Predict / Compounds / SCHEMBL248384

SCHEMBL248384

SCHEMBL248384

O=C(O)[C@@H]1C[C@H]1c1ccc(F)c(F)c1

nearest known ligand 0.50

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 4/20 0.50
▸ SLC9A1 P19634 1/20 0.48
▸ HTR2A P28223 1/20 0.47
▸ HTR2C P28335 1/20 0.47
▸ HTR2B P41595 1/20 0.47
▸ KDM1A O60341 2/20 0.47
▸ CYP4F2 P78329 3/20 0.44
▸ CYP4A11 Q02928 3/20 0.44
▸ GPR88 Q9GZN0 1/20 0.43
▸ FFAR4 Q5NUL3 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7655989 1.00 FFAR1 (0.50) FFAR1SLC9A1HTR2AHTR2CHTR2B
SCHEMBL12915852 1.00 FFAR1 (0.50) FFAR1SLC9A1HTR2AHTR2CHTR2B
SCHEMBL18272394 1.00 FFAR1 (0.50) FFAR1SLC9A1HTR2AHTR2CHTR2B
SCHEMBL15196464 1.00 FFAR1 (0.50) FFAR1SLC9A1HTR2AHTR2CHTR2B
SCHEMBL18272446 1.00 FFAR1 (0.50) FFAR1SLC9A1HTR2AHTR2CHTR2B
SCHEMBL29488083 1.00 FFAR1 (0.50) FFAR1SLC9A1HTR2AHTR2CHTR2B
SCHEMBL248385 1.00 FFAR1 (0.50) FFAR1SLC9A1HTR2AHTR2CHTR2B
SCHEMBL15189650 0.98 FFAR1 (0.49) FFAR1SLC9A1HTR2AHTR2CHTR2B
SCHEMBL814567 0.86 SLC9A1 (0.48) SLC9A1HTR2AHTR2CHTR2BKDM1A
SCHEMBL247915 0.86 SLC9A1 (0.48) SLC9A1HTR2AHTR2CHTR2BKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117209393-A Preparation method of aromatic cyclopropyl formamide 泓博智源(开原)药业有限公司 2023-12-12 — — CN claimed
CN-110437092-B Preparation method of ticagrelor key intermediate aromatic cyclopropane amide 泓博智源(开原)药业有限公司 2022-06-10 — — CN claimed
WO-2013144295-A1 SYNTHESIS OF 2-(3,4-DIFLUOROPHENYL)CYCLOPROPANAMINE DERIVATIVES AND SALTS SANDOZ AG (CH) 2013-10-03 — — WO claimed
EP-2644590-A1 Synthesis of 2-(3,4-difluorophenyl)cyclopropanamine derivatives and salts LEK Pharmaceuticals d.d. (SI) 2013-10-02 — — EP claimed
US-8278475-B2 Processes for the preparation of optically active intermediates ASTRAZENECA AB (SE) 2012-10-02 — — US claimed
US-20120136167-A1 Processes For The Preparation Of Optically Active Intermediates ASTRAZENECA AB (SE) 2012-05-31 — — US claimed
US-20110190520-A1 Process for the preparation of cyclopropyl carboxylic acid esters and derivatives ASTRAZENECA AB (SE) 2011-08-04 — — US claimed
US-20060258879-A1 Process for the preparation of cyclopropyl carboxylic acid esters and derivatives ASTRAZENECA AB (SE) 2006-11-16 — — US claimed
CN-115894496-B Preparation method of ticagrelor and intermediate thereof 上海贝美医药科技有限公司 2025-03-21 — — CN disclosed
CN-117209393-A Preparation method of aromatic cyclopropyl formamide 泓博智源(开原)药业有限公司 2023-12-12 — — CN disclosed
CN-117209393-A Preparation method of aromatic cyclopropyl formamide 泓博智源(开原)药业有限公司 2023-12-12 — — CN disclosed
WO-2023223335-A1 A METHOD FOR PREPARING (1S)-2-CHLORO-1-(3,4-DIFLUOROPHENYL) ETHANOL AARTI PHARMALABS LIMITED (IN) 2023-11-23 — — WO disclosed
WO-2023125846-A1 COMPOUND FOR PREVENTING AND TREATING CORONAVIRUS INFECTION, CONJUGATE THEREOF AND METHOD THEREFOR 苏州爱科百发生物医药技术有限公司 2023-07-06 — — WO disclosed
CN-115894496-A Preparation method of ticagrelor and intermediate thereof 上海贝美医药科技有限公司 2023-04-04 — — CN disclosed
US-7122695-B2 Process for the preparation of cyclopropyl carboxylic acid esters and derivatives ASTRAZENECA AB (SE) 2006-10-17 — — US disclosed
US-20060041132-A1 Novel triazolo pyrimidine compounds ASTRAZENECA AB (SE) 2006-02-23 — — US disclosed
EP-0996621-B1 TRIAZOLO[4,5-d]PYRIMIDINE DERIVATIVES AS ANTI-THROMBOTIC AGENTS ASTRAZENECA AB (SE) 2003-10-01 — — EP disclosed
EP-1056749-B1 NOVEL TRIAZOLO(4,5-d)PYRIMIDINE COMPOUNDS ASTRAZENECA UK LTD (GB) 2003-02-19 — — EP disclosed
US-6369064-B1 MYOCARDIAL INFARCTION AND UNSTABLE ANGINA; P2T-RECEPTOR ANTAGONISTS; ANTITHROMBOTIC AGENTS; 7-(SUBSTITUTED AMINO) -5-(THIO)-3H-1,2,3-TRIAZOLO(4,5-D)PYRIMIDIN-3-YL) -CYCLOPENTANECARBOXAMIDES ASTRAZENECA AB (SE) 2002-04-09 — — US disclosed
US-6251910-B1 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists ASTRAZENECA UK LIMITED (GB) 2001-06-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258879-A1 Process for the preparation of cyclopropyl carboxylic acid esters and derivatives MCCC2, DHPS, CYP3A4 FFAR1 1263/4885SLC9A1 4322/4885HTR2A 3833/4885
US-20060041132-A1 Novel triazolo pyrimidine compounds TYMS, TYMP, DPYD FFAR1 4291/4885SLC9A1 4604/4885HTR2A 2776/4885
US-20110190520-A1 Process for the preparation of cyclopropyl carboxylic acid esters and derivatives MCCC2, DHPS, CYP3A4 FFAR1 1263/4885SLC9A1 4322/4885HTR2A 3833/4885
US-20120136167-A1 Processes For The Preparation Of Optically Active Intermediates DHPS, CYP2S1, CYP1B1 FFAR1 1117/4885SLC9A1 4566/4885HTR2A 315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.